Dermapharm Holding SECHIX:DMPD 80 EV-to-EBIT is 12.67 as of Jul. 11, 2026, which is 1% below its 10-year median of 12.83. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €39.87. The stock has 10 warning signs investors should review. Among 689 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 60.23% on this metric.
Dermapharm Holding SE (CHIX:DMPd) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Dermapharm Holding SE's Enterprise Value for the quarter that ended in Mar. 2026 was €1,650 Mil.
Dermapharm Holding SE's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €244 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DMPD vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's EV-to-EBIT falls into.
Dermapharm Holding SE's current Enterprise Value is €3,089 Mil.
Dermapharm Holding SE's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €244 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (CHIX:DMPD) has a EV-to-EBIT of 12.67 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dermapharm Holding SE and its competitors. This is near median its historical median of 12.83. Over the past decade, Dermapharm Holding SE's EV-to-EBIT has ranged from 6.56 to 29.02. According to the industry distribution chart, Dermapharm Holding SE ranks #274 out of 689 companies in the Drug Manufacturers industry, placing it in the top 39.8%.
Is Dermapharm Holding SE's EV-to-EBIT too high?
Dermapharm Holding SE's current EV-to-EBIT of 12.67 is near median its 10-year median of 12.83. Over the past 10 years, this metric has ranged from a low of 6.56 to a high of 29.02. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Dermapharm Holding SE's value of 12.67 is 19.9% below this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #274 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #274 out of 689 companies for EV-to-EBIT. This puts Dermapharm Holding SE in the upper half of its industry. The industry median EV-to-EBIT is 15.81. Dermapharm Holding SE's value of 12.67 is 19.9% below this benchmark. Historically, Dermapharm Holding SE's own EV-to-EBIT has ranged from 6.56 to 29.02 over the past decade. While the company's 10-year median is 12.83 vs. the industry median of 15.81, Dermapharm Holding SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current EV-to-EBIT of 12.67 is 19.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current EV-to-EBIT is 12.67, which is near median its own 10-year median of 12.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current EV-to-EBIT of 12.67. The stock's GF Value™ is €39.87, compared to a current price of €46.18 — trading 15.8% above its estimated fair value. The current EV-to-EBIT is 12.67, which is near median its 10-year median of 12.83 and 19.9% below the Drug Manufacturers industry median of 15.81. Dermapharm Holding SE's overall GF Score™ is 80/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current EV-to-EBIT is 12.67 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 15.8% above its estimated GF Value™ of €39.87.
Key valuation signals for CHIX:DMPD:
EV-to-EBIT: 12.67 (near median its 10-year median of 12.83)
GF Value™: €39.87 vs. price of €46.18 (15.8% above fair value)
Industry Position: 19.9% below the Drug Manufacturers median (#274 of 689)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
